Oklahoma Senate Bill SB1030

Oklahoma 2026 Regular Session

• Introduced: 2/3/25
• Refer: 2/4/25

Caption

Prescription drug pricing; prohibiting certain action. Effective date.

Impact

The passage of SB1030 will significantly impact state laws regarding prescription drug pricing, particularly as it relates to the treatment of 340B entities within Oklahoma. By restricting the ability of health insurers and pharmacy benefits managers to impose lower reimbursement rates or additional fees on 340B drugs, the bill aims to protect the financial viability of these entities. Supporters argue that this will ultimately benefit patients who rely on these services for their medication needs. However, critics may raise concerns about how these restrictions might increase overall drug costs for other consumers if not managed effectively.

Summary

Senate Bill 1030, known as the 340B Drug Pricing Nondiscrimination Act, aims to prohibit discriminatory practices against 340B entities which participate in a federal drug pricing program. This legislation establishes new requirements and restrictions on health insurance issuers and pharmacy benefits managers regarding their reimbursement practices for drugs purchased under the 340B program. The bill defines specific terms, including what constitutes a 340B entity, and imposes penalties for those who engage in prohibited actions against such entities. By ensuring that 340B entities are reimbursed fairly and are not subject to discriminatory terms compared to non-340B entities, SB1030 seeks to enhance access to affordable medications for patients served by these entities.

Contention

Notable points of contention surrounding SB1030 include concerns from some stakeholders regarding the potential for increased costs to the health insurance system. Opponents may argue that while the bill aims to protect 340B pricing, it could inadvertently drive up premiums for all insured individuals as costs are redistributed. Further, there is the contention concerning how the act of enforcing these restrictions will be managed by the Oklahoma Attorney General's office, including the procedural frameworks needed to handle violations by pharmacy benefits managers and health insurers. The implementation of fines and penalties for non-compliance may also spark debate regarding the appropriateness of enforcement measures.